Analytical Data
-
基因名
FGFR-4
-
简介
The FGFR-4 protein is a cell surface receptor for tyrosine kinase and fibroblast growth factor. FGFR4, a receptor for FGF-1 and FGF-3 highly expressed in cancer cells, promotes tumor progression in colon cancer by activating Mek/Erk and MMP-7. FGFR-4 Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived FGFR-4 protein, expressed by HEK293 , with C-mFc labeled tag.
- Application
-
别名
Fibroblast growth factor receptor 4; FGFR-4; CD334; JTK2; TKF
-
种属
Rhesus Macaque
-
表达系统
HEK293
-
标签
C-mFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
XP_001087243.1
-
表达区间
L22-D369
-
蛋白长度
Partial
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast Growth Factor Receptor 4 (FGFR4) is a member of the fibroblast growth factor receptor family, which plays a crucial role in various biological processes, including cell growth, differentiation, and metabolism. FGFR4 is particularly associated with the progression of several types of cancers, such as hepatocellular carcinoma and prostate cancer, where its overexpression correlates with poor prognosis. Given its significant role in tumorigenesis, FGFR4 has emerged as a potential therapeutic target, driving research into the development of FGFR4-specific inhibitors and therapies. The study of FGFR4 recombinant proteins is vital for understanding its structure-function relationships and interactions with ligands, which can inform the design of selective inhibitors. Furthermore, recombinant FGFR4 proteins facilitate the investigation of downstream signaling pathways, such as the MAPK and PI3K/Akt pathways, that are activated upon FGFR4 engagement. Advances in biotechnological methods have enabled the production of these proteins in various systems, allowing researchers to conduct detailed functional assays and structural analyses. Overall, the characterization of FGFR4 recombinant proteins is a foundational step in developing targeted therapeutics aimed at treating FGFR4-driven malignancies and improving clinical outcomes for patients.
